OOIR: Observatory of International Research

Papers

(The TQCC of Nature Reviews Rheumatology is 12. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)

Article	Citations
Low-dose rituximab can go even lower	680
No benefit from adding MTX to ustekinumab	435
Inflammatory arthritis affects men’s fertility	373
Bimekizumab effective across the axSpA spectrum	354
SLC26A2 deficiency, matrix stiffness and mechanotransduction linked in osteoporosis	327
Genome-wide mutagenesis reported in systemic sclerosis	274
Reply to ‘Potential benefit of anticoagulation in Behçet syndrome’	252
Rheumatic diseases on the rise	242
A role for TGFβ and EBV in MIS-C pathogenesis	222
The role of the patient in rheumatology	193
Biological and clinical roles of IL-18 in inflammatory diseases	172
COVID-19 in people with rheumatic diseases: risks, outcomes, treatment considerations	169
Towards better management of sterile bone inflammation	159
New drug formulation reduces bone loss	156
Use of platelet-rich plasma for knee OA not supported by RCT results	144
To choose or not? The value of discrete-choice experiments in rheumatology	131
FOXP3 splice variant is associated with autoimmune disease	131
Urchin-like nanoparticles for miRNA therapy of OA	127
The value of comparative efficacy studies in informing rheumatology guidelines	126
The 2022 ACR vaccination guideline: a call-to-action	122
Imbalance of threat and soothing systems in fibromyalgia: rephrasing an established mechanistic model?	117
Down syndrome: insights into autoimmune mechanisms	112
MIS-C: myths have been debunked, but mysteries remain	112
Addressing the challenge of global delays in diagnosis and treatment of systemic lupus erythematosus	111
Inflammation across tissues: can shared cell biology help design smarter trials?	110

Appraising the evolving landscape of protease inhibition in osteoarthritis	104
2021 ACR guideline for JIA reflects changes in practice	103
Low-dose glucocorticoids benefit seniors with RA	102
Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician	102
Co-trimoxazole reduces mortality in anti-MDA5-DM	99
Low back pain is a growing concern	97
Pain in systemic lupus erythematosus: emerging insights and paradigms	91
Guiding ILD management in systemic autoimmune rheumatic diseases	91
Wnt-induced IGF1 drives OA	91
Publisher Correction: Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician	89
Biologics in rheumatoid arthritis: a lifetime treatment or possibility of drug holidays?	89
Calprotectin tracks tocilizumab-treated RA	86
Author Correction: Proposals for the rheumatological use of JAK inhibitors	86
A direct link between SARS-CoV-2 and bone loss	85
S100A4 inhibition targets fibrosis in SSc	84
Rheumatic diseases and metabolism: where centre and periphery meet	83
Fumarate drives interferon release in systemic sclerosis monocytes	79
Distinct mucosal endotypes as initiators and drivers of rheumatoid arthritis	78
Sexual dimorphism in the prevalence, manifestation and outcomes of axial spondyloarthritis	77
Rheumatology in the digital health era: status quo and quo vadis?	77
Antibiotics keep rheumatic heart disease at bay	77
Erosive cargo from synovial fibroblasts	72
Targeting the IVD clock to halt degeneration	70
Which DMARD for ICI-associated arthritis?	70
sCD13 role in arthritis mediated via bradykinin receptor	69
CAR T cells induce drug-free SLE remission	68
Publisher Correction: Recent advances in the diagnosis and management of neuropsychiatric lupus	67
Insights into IVDD pathogenesis in 2024	65
ERAP1 and the return of the UPR in ankylosing spondylitis	64
Macrophage-coated nanocarriers for gouty arthritis	63
A path towards personalized medicine for autoinflammatory and related diseases	61
International Guideline for Idiopathic Inflammatory Myopathy-Associated Cancer Screening: an International Myositis Assessment and Clinical Studies Group (IMACS) initiative	60
Phase III trial of telitacicept in SLE	59
PGE2 receptor antagonist has potential to treat osteoarthritis	59
Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach	59
Chimeric receptors broaden the therapeutic landscape for autoimmune disease	59
TASL has a key role in SLE	57
Blocking CDK7 attenuates inflammatory arthritis	57
RA risk from occupational inhalation	57
PPIs linked to increased risk of knee replacement	56
Improving the design of RCTs in non-radiographic axial spondyloarthritis	54
Two sides of management recommendations for psoriatic arthritis	51
All fibroblasts are equal, but some are more equal than others	51
Repolarizing macrophages using antagomirs	50
New developments in electronic health record analysis	48
A leading role for interferon as a treatment target in Sjögren syndrome	48
Profiling joint tissues at single-cell resolution: advances and insights	47
Pan American League of Associations for Rheumatology recommendations for the management of axial spondyloarthritis	47
New hope for B cell-targeting therapy in pSS	46
New refinements aim to optimize articular cartilage tissue engineering	45

A critical view of WHO guidelines on management of low back pain	45
Platelets as drivers of immunothrombosis in rheumatic diseases	42
APOE in fat pad and synovium contributes to knee OA	41
Clarity for the language of race, ethnicity and genetic ancestry in rheumatology	40
Author Correction: Glycobiology of rheumatic diseases	40
Publisher Correction: The impact of COVID-19 on rare and complex connective tissue diseases: the experience of ERN ReCONNET	40
AhR promotes suppressor cell function in Sjögren syndrome	39
Piezo1 induces new bone formation in AS	38
l-arginine inhibits arthritis and bone loss by reprogramming osteoclast metabolism	37
IL-1 and autoinflammatory disease: biology, pathogenesis and therapeutic targeting	37
Treg cell-inducing nanoparticles show promise for treating OA	36
Pathogenic antibodies target stromal antigens in RA	35
Author Correction: International Guideline for Idiopathic Inflammatory Myopathy-Associated Cancer Screening: an International Myositis Assessment and Clinical Studies Group (IMACS) initiative	35
CXCL5 effective in mouse model of SLE	34
Sex- and gender-based personalized medicine in rheumatology	34
Shifting the SLE management paradigm: challenges and implications	33
Imaging for prediction of RA development	33
PDGFR signalling implicated in anti-resorptive effects of sclerostin blockade	32
BiTE therapy for rheumatic diseases	32
Interferon disrupts immune and tissue homeostasis in SLE via CXCL13	31
Parathyroid hormone receptor agonists in the management of osteoporosis	31
In vivo CAR-T cell engineering in refractory SLE	29
HLA autoimmunity risk alleles influence T cell receptor sequences	29
Critical appraisal of serum urate targets in the management of gout	29
STING-driven necroptosis linked to autoinflammatory disease	28
Location-specific treatment of chronic inflammatory joint disease	27
Post-transcriptional checkpoints in autoimmunity	26
FABP4 exacerbates RA	26
Mechanisms and clinical implications of intervertebral disc calcification	26
PLG nanoparticles target inflammatory monocytes in SSc	24
Detachment promotes RA synovial fibroblast survival and invasiveness	23
Guselkumab effective through 2 years in PsA trial	23
Multi-omics reveals distinct MPA subtypes	22
State-of-the-art evidence in the treatment of systemic sclerosis	22
Adropin inhibits fibrosis in SSc	22
Complement therapeutics are coming of age in rheumatology	21
Notch signalling mediates OA pain in mice	21
COVID-19 linked to rise in anti-MDA5 autoimmunity	21
Evidence-Based Guideline for the diagnosis and management of eosinophilic granulomatosis with polyangiitis	20
Busting the myth of methotrexate chronic hepatotoxicity	20
The potential contribution of in silico studies to improved treatment of osteoarthritis	20
Update on the pathophysiology and treatment of primary Sjögren syndrome	19
How the COVID-19 pandemic has affected rheumatology research	19
Citrulline immunity in RA: CD8+ T cells enter the scene	19
Single-cell RNA sequencing sheds light on cell-type specific gene expression in immune cells	19
Shedding light onto the immunometabolic effects of glucocorticoids	18
Treatment of non-systemic juvenile idiopathic arthritis	18
The immune health metric as an indicator of health and disease	18
Synovial fluid as a complex molecular pool contributing to knee osteoarthritis	18
Mechanisms of joint destruction in rheumatoid arthritis — immune cell–fibroblast–bone interactions	18
UNC93B1 variants promote SLE via TLR activation	17
Primary care rheumatology: towards sustainable development in health	17
No benefit to intensive urate lowering in gout	17
Undiagnosed axSpA is prevalent in IBD	17
The PU.1– IL-9 axis in TH9 cells promotes RA	16
Rheumatoid arthritis prevention in arthralgia: fantasy or reality?	15
Bone-modifying drugs slow OA progression	15
Glycosylation switch in synovial fibroblasts promotes ECM degradation	15
Lupus ABC spearheading a new era of collaboration to advance lupus drug development	15
More than a leaky gut: how gut priming shapes arthritis	15
Combination therapy for Behçet uveitis	15
Advances in viscosupplementation and tribosupplementation for early-stage osteoarthritis therapy	14
New guide calls for interdisciplinary approach to TMJ arthritis symptoms	14
Cellular metabolic adaptations in rheumatoid arthritis and their therapeutic implications	14
The role of the immune system in osteoarthritis: mechanisms, challenges and future directions	14
Interleukin-2 and regulatory T cells in rheumatic diseases	14
Low-frequency and rare genetic variants associated with rheumatoid arthritis risk	14
Advances in the calculation of minimal important change estimates for patient-reported outcome measures	13
T cell differentiation in Sjögren syndrome is regulated by TOX	13
Reply to: Is classifying SSc-ILD drugs as either immunosuppressive or anti-fibrotic misleading?	13
Reversal of inflammatory priming prevents arthritic flares	13
Paediatric glucocorticoid toxicity index: new possibilities in assessment	13
The pathogenesis of gout: molecular insights from genetic, epigenomic and transcriptomic studies	12
Phenotypic heterogeneity in psoriatic arthritis: towards tissue pathology-based therapy	12
Global epidemiology of spondyloarthritis	12
Current challenges in understanding the epidemiology of calcium pyrophosphate crystal deposition	12